Ferrous sulfate
Tardyferon contains iron.
The need for iron is increased in women during pregnancy, postpartum, in breastfeeding mothers, and in adolescents during growth. Iron deficiency or iron deficiency anemia can be prevented or treated with a medicine called Tardyferon.
In combination with iron and excipients, Fe ions are released slowly, which allows avoiding the sudden absorption of the entire dose of iron into the blood serum.
This reduces the number of observed side effects and makes it easier for the patient to follow the recommendations. The slow release of the medicine allows iron ions to reach the final sections of the intestine, which, in addition to the duodenum, have the ability to absorb iron. The limitation of iron absorption to the upper segments of the intestine is due to the iron saturation process. Like all iron-containing medicines, Tardyferon has no effect on erythropoiesis (red blood cell production) or anemia caused by factors other than iron deficiency.
Tardyferon is used to treat iron deficiency anemia and to prevent iron deficiency in pregnant women with inadequate dietary intake.
Tardyferon is indicated for use in children over 10 years of age and adults.
or one that is associated with an excess of iron in the body (e.g., thalassemia, anemia resistant to treatment or caused by bone marrow failure).
Before starting to use Tardyferon, you should discuss it with your doctor or pharmacist.
A toxic dose of iron is lower for children than for adults. It is not recommended to give Tardyferon to children under 10 years of age.
If the patient is receiving Tardyferon due to iron deficiency anemia, the doctor will combine therapy with diagnosis and treatment of the cause of the disease.
If iron deficiency anemia occurs in the course of inflammatory diseases, treatment with Tardyferon will not be effective.
If the patient has difficulty swallowing, they should tell their doctor.
If the tablet accidentally enters the patient's airways (aspiration of the tablet), it may cause injuries such as necrosis (tissue death) or bronchitis (inflammation of the main airways in the lungs) or esophagitis (inflammation of the esophagus). These, in turn, can lead to bronchial narrowing. It is possible for symptoms such as persistent cough, coughing up blood, and (or) shortness of breath to occur, even if aspiration occurred several days to several months before the onset of these symptoms.
In the event of improper swallowing and the occurrence of one or more of the mentioned symptoms in the patient, you should immediately contact a doctor or the nearest emergency department to determine if there has been damage to the airways and to receive proper treatment.
In medical literature, gastrointestinal melanosis (discoloration of the gastrointestinal tract) has been described in elderly patients with renal failure, diabetes (abnormally high blood sugar levels), and (or) hypertension (high blood pressure) treated with several medications for these conditions and receiving iron supplementation due to accompanying anemia. If the patient is to undergo surgery in the gastrointestinal tract, the surgeon should be informed about the use of iron, as melanosis may make the surgical procedure more difficult.
There have been reports of stomach ulcers and stomach bleeding in patients taking iron tablets. If such symptoms occur, the doctor may recommend changing the tablets to a liquid medicine (see section 4).
Due to the risk of oral ulcers and tooth discoloration, the tablets should not be sucked, chewed, or held in the mouth, but swallowed whole, washed down with water. If following these instructions is not possible or there are difficulties with swallowing, you should contact a doctor.
Tardyferon can be used in children over 10 years of age.
You should not take Tardyferon unless your doctor decides to do so.
You should tell your doctor about all the medicines you are currently taking or have recently taken, as well as the medicines you plan to take.
Some medicines cannot be taken at the same time, while others require special changes (e.g., time of administration).
You should avoid taking Tardyferon if you are taking iron-containing medicines for injection.
You should not take Tardyferon within 2 hours of taking a dose of any of the following medicines:
Consuming large amounts of coffee, tea, or red wine may reduce iron absorption.
It is not recommended to take this medicine at the same time as whole grain products (bran, legumes, oilseeds), certain proteins (e.g., eggs), or foods or drinks containing calcium (cheese, milk, etc.). You should maintain a gap between taking iron salts and these foods (at least 2 hours).
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine.
There are no studies in pregnant women in the first trimester that would allow assessing the risk of birth defects. However, neither in medical literature nor during the post-marketing period have any cases of congenital defects been reported. Numerous literary data on women in the second and third trimesters of pregnancy do not indicate an increased risk of defects or toxicity to the fetus or newborn. Therefore, Tardyferon can be used during pregnancy if it is clinically indicated.
Iron passes into breast milk in small amounts. The mother's diet does not affect its concentration. No effect on newborns/infants is expected. Tardyferon can be used during breastfeeding.
It is unlikely that Tardyferon will affect your ability to drive or use machines.
Tardyferon contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
This medicine should always be used as directed by your doctor or pharmacist. If you are unsure, you should consult your doctor or pharmacist.
Tardyferon is indicated for children over 10 years of age and adults.
The medicine is administered orally.
Treatment of iron deficiency anemia
Children over 10 years of age and adults: 1 to 2 tablets per day.
The duration of treatment should be long enough to correct anemia and replenish iron stores.
Treatment may last at least 3 to 6 months and can be extended if necessary in agreement with your doctor.
Prophylactic treatment
Tardyferon tablets are administered orally.
You should swallow the tablet whole, washed down with water. Do not suck, chew, or hold it in your mouth.
Tablets should be taken with a large glass of water, preferably before or during a meal, depending on gastrointestinal tolerance (except for specific foods mentioned in the section "Tardyferon with food, drinks, and alcohol").
If you have taken too much of the medicine, you should immediately contact your doctor or the nearest emergency department to receive proper treatment, especially if the overdose occurred in a child.
Symptoms of overdose include:
Long-term consequences of overdose, such as narrowing of the gastrointestinal tract (stenosis), characterized by nausea, bloating, constipation, and abdominal distension, are also possible.
If you miss a dose at the usual time, you should take it as soon as possible. However, if it is almost time for the next dose, you should not take the missed dose and take the next tablet as usual.
You should not take a double dose to make up for the missed dose.
If you have any further doubts about using this medicine, you should consult your doctor or pharmacist.
Tardyferon should be used for as long as your doctor recommends. If you stop the treatment too early, the disease may recur.
If you have any further doubts about using this medicine, you should consult your doctor or pharmacist.
Like all medicines, Tardyferon can cause side effects, although not everybody gets them.
The following side effects may occur, listed in order of decreasing frequency:
Constipation, diarrhea, feeling of stomach fullness, abdominal pain, dark stool color, nausea.
Throat swelling (laryngeal edema), abnormal stools, indigestion, vomiting, stomach inflammation, itching, red rash (erythematous rash).
Allergic reaction (hypersensitivity reaction), itching rash (urticaria), death of lung tissue cells (pulmonary necrosis)*, lung tissue inflammation (pulmonary granuloma)*, narrowing of the airways (bronchial stenosis)*, throat ulcers*, changes in the esophagus*, esophageal ulcers*, tooth discoloration**, oral ulcers**, discoloration of the gastrointestinal tract (gastrointestinal melanosis, see section 2), stomach ulcers, stomach bleeding (see section 2).
* Patients, especially the elderly and those with swallowing difficulties, may also be at risk of throat or esophageal ulcers. If the tablet enters the airways, there is a risk of bronchial ulcers and pulmonary granuloma (inflammatory condition), which can lead to bronchial narrowing. In the event of improper administration, you should immediately contact your doctor or the nearest emergency department to receive proper treatment.
** In the event of improper administration, when tablets are chewed, sucked, or held in the mouth.
In medical literature, gastrointestinal melanosis (discoloration of the gastrointestinal tract) has been described in elderly patients with chronic kidney disease, diabetes (high blood sugar levels), and (or) hypertension (high blood pressure) treated with several medications for these conditions and receiving iron supplementation due to accompanying anemia.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging.
The expiry date refers to the last day of the specified month.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
30 prolonged-release tablets in a cardboard box.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Pierre Fabre Ibérica, S.A.
Ramón Trias Fargas, 7-11
08005 Barcelona
Spain
Pierre Fabre Médicament Production
Site PROGIPHARM
Rue du Lycée
45500 Gien
France
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Spain, the country of export:672908.3
Parallel import authorization number:126/15
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.